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Aim: Current enoxaparin dosing guidelines in children are based on total body
weight. This is potentially inappropriate in obese children as it may overestimate the
drug clearance. Current evidence suggests that obese children may require lower initial doses of enoxaparin, therefore the aim of this work was to characterise the pharmacokinetics of enoxaparin in obese children and to propose a more appropriate
dosing regimen.
Methods: Data from 196 unique encounters of 160 children who received enoxaparin treatment doses were analysed. Enoxaparin concentration was quantified using
the chromogenic anti factor Xa (anti-Xa) assay. Patients provided a total of 552 antiXa samples. Existing published pharmacokinetic (PK) models were fitted and evaluated against our dataset using prediction-corrected visual predictive check plots
(pcVPCs). A PK model was fitted using a nonlinear mixed-effects modelling approach.
The fitted model was used to evaluate the current standard dosing and identify an
optimal dosing regimen for obese children.
Results: Published models of enoxaparin pharmacokinetics in children did not capture
the pharmacokinetics of enoxaparin in obese children as shown by pcVPCs. A onecompartment model with linear elimination best described the pharmacokinetics of
enoxaparin. Allometrically scaled fat-free mass with an estimated exponent of 0.712
(CI 0.66-0.76) was the most influential covariate on clearance while linear fat-free
mass was selected as the covariate on volume. Simulations from the model showed
that fat-free mass-based dosing could achieve the target anti-Xa activity at steady
state in 77.5% and 78.2% of obese and normal-weight children, respectively, compared to 65.2% and 75.5% for standard total body weight-based dosing.
Conclusions: A population PK model that describes the time course of anti-Xa activity of enoxaparin was developed in a paediatric population. Based on this model, a
unified dosing regimen was proposed that will potentially improve the success rate of
target attainment in overweight/obese patients without the need for patient body
size categorisation. Therefore, prospective validation of the proposed approach is
warranted.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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I N T RO DU CT I O N
What is already known about this subject

Enoxaparin is a commonly used anticoagulant for treating and preventing thromboembolic disorders in children. Common indications

• Enoxaparin is typically dosed in children on a milligrams

for enoxaparin include deep venous thrombosis/pulmonary embolism,

per kilogram basis, which may be suboptimal when used

coronary heart disease and prophylaxis in cases of increased throm-

in obese children.

botic risk such as surgery and infections. Enoxaparin has largely

• With standard dosing, obese children achieve higher anti-

replaced unfractionated heparin as the parenteral anticoagulant of

Xa activity and require more frequent dose reduction

choice for the management of thrombosis due to favourable pharma-

compared to normal-weight children.

cokinetic properties such as a longer half-life and higher subcutaneous

• No alternative dosing regimens for enoxaparin have been

bioavailability. It has been shown to achieve similar effectiveness

proposed/explored in obese children.

without an increase in the incidence of major bleeding events.1 This
has been purported to be due to a more predictable dose-response
relationship.2

What this study adds

Dosing guidelines of enoxaparin for paediatric patients typically
suggest an initial treatment dose of 1 mg/kg (of total body weight)

• The first population model was developed for enoxaparin

twice daily, targeting a peak (4 hours post-dose) anti-Xa (aXa) activity

pharmacokinetics in obese children.

of 0.5-1 IU/mL.3,4 A recent population analysis showed that this dose

• The model was used to identify a dosing regimen of

has a 72.3% probability of achieving the aXa concentration target in

enoxaparin that consistently achieves the target anti-Xa

hospitalised paediatric patients.5 Maintenance dosing based on total

activity in both obese and normal-weight children.

body weight (Wt) implies that enoxaparin clearance is linearly propor-

• The proposed regimen potentially eliminates the need for

tional to Wt. However, this has often been found to be inaccurate in

categorising children based on their body weight and

overweight/obese individuals.6,7 As the body's metabolic processes

simplifies dose calculation in clinical practice.

occur primarily in lean tissues, overweight/obese individuals tend to
have lower drug clearance per kilogram of Wt. Therefore, dosing
based on Wt will potentially result in overdosing in this population. It
has been reported that overweight/obese children achieve a significantly higher aXa activity compared to nonobese children when dosed

practices also implement dose capping at 100 mg per dose.15 No

on a Wt basis.8 A recent review has shown that overweight/obese

alternative dosing strategies have been used or explored in the

paediatric patients required a 12.9% to 37.3% average dose reduction,

paediatric population.

suggesting they may require lower initial enoxaparin Wt-based
doses.9 Data on the clinical outcomes of enoxaparin treatment in

1.1

|

Objectives

overweight/obese children versus normal-weight children are lacking.
However, elevated aXa levels are associated with a higher risk of

The objectives of this study were (1) to evaluate the performance of

adverse effects such as bleeding.

published models of enoxaparin pharmacokinetics against our dataset

The issue of dosing obese patients is becoming more critical as

in both normal-weight and overweight/obese children, (2) to develop

the prevalence of obesity is increasing worldwide.10 Obesity in adults

and evaluate a population pharmacokinetic (PK) model to predict the

is usually defined based on the absolute value of body mass index

optimal dosing regimen of enoxaparin in overweight/obese paediatric

(BMI).10 However, children are classified as overweight if their BMI is

patients and (3) to evaluate the current dosing guidelines in

greater than the 85th but less than the 95th percentile respective to

overweight/obese children and identify optimal dosing strategies for

age and sex, whereas obesity is defined as a BMI exceeding the 95th

those patients.

11

percentile for age and sex.

In adults, the risk of overdosing obese

patients is minimised through alternative practices. A popular alterna-

2

METHODS

|

tive to dosing in the obese is to reduce the dose to 0.75 mg/kg twice
daily.12 However, this approach has only been assessed in morbidly

2.1

|

Data

obese patients. An alternative dosing strategy is based on fat-free
mass (FFM), which has been shown to result in fewer bleeding/

The data used in this analysis consisted of retrospectively collected

bruising events without a decrease in drug effectiveness.13,14 Some

aXa measurements from 160 paediatric patients who received a
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treatment dose of enoxaparin between 1 January 1996 and

activity in the included data was 0.58 U/mL (IQR 0.42-0.81 IU/mL).

31 December 2016 in the Primary Children's Hospital, Salt Lake City,

The demographics of the population of this study are summarised in

Utah, USA, and had at least one recorded aXa measurement. The

Table 1. Figure 1 shows the distribution of age versus weight in the

study received approval from the University of Utah institutional

study sample broken down by sex and body size category.

review board (IRB# 01101489). All patients who concomitantly
received other anticoagulants were excluded from the study. As per
institutional protocol, infants younger than 2 months received

2.2

|

Evaluation of published models

1.5 mg/kg every 12 hours while older infants and children received
1 mg/kg every 12 hours. aXa activity was determined using the

Two population PK models of enoxaparin in children were identified.

chromogenic one-stage assay (Heparin anti-Xa LMWH 0030144 kit;

The first described the pharmacokinetics of enoxaparin in children

Diagnotsica Stago, Milan, Italy) with a lower limit of quantification of

younger than 1 year of age,17 while the other examined children

0.1 IU/mL. The intra-assay coefficient of variation was 3%. Patients

between 1 and 18 years of age.5 Both models, described in detail in

were categorised as overweight or obese if their BMIs were higher

Appendix S1, were fitted to the data of this study and then evaluated

than the 85th or 95th percentile, respectively, for their age and sex as

using prediction-corrected visual predictive check (pcVPC) plots to

per the Centres for Disease Control and Prevention (CDC) growth

determine model fit to the whole dataset and fit to specific patient

charts.16

subpopulation based on size categories.

One hundred and sixty patients who provided 552 aXa samples
during 196 unique encounters met the inclusion criteria and were
available for this analysis. Patients received a median enoxaparin dose

2.3

|

Model building

of 1.16 mg/kg (interquartile range [IQR] 0.93-1.39 mg/kg) twice daily.
Dose adjustment based on measured aXa occurred in 7.29% of dosing

Data from all 160 patients who met the inclusion criteria were

records, of which 35.12% were dose reductions and 13.17% were in

included in the model-building process. Two patients had no recorded

overweight/obese patients. The median number of doses per

value of height or weight. These were imputed with a single

encounter was 10 (IQR 7-14 dose/encounter) and the median aXa

imputation from a multivariate distribution of age, sex, weight and
height. The root mean squared errors for the imputation of weight
and height were 0.854 kg and 11.9 cm, respectively. The final model

TABLE 1

Demographic characteristics of the study population

Characteristic

Median or n

Range or %

Sex (male/female)

92/68

57.5/42.5

Weight (kg)

19.2

1.51-151

Age (years)

5.85

0.0004-18

Number of observations per
encounter

3

1-13

Body mass index (kg/m2)

16.58

8.44-52.35

Number of overweight/obese

34

21.3

was re-estimated with the data from patients with missing weight/
height excluded and estimates were compared to the full dataset.
One- and two-compartment models with linear and nonlinear
elimination and zero- and first-order absorption were tested to
describe the kinetics of aXa activity. Covariates considered on model
parameters were postnatal age (Age), postmenstrual age (PMA)
(calculated as age + 40 weeks), sex, Wt, BMI,18 FFM,19 body surface
area (BSA),20 normal fat mass (NFM),21 and allometrically scaled Wt
and FFM with fixed (0.75 or 0.67) or estimated exponents (see
Equations 1-5).

F I G U R E 1 The distribution of age
versus weight in the study sample broken
down by sex and body size category
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Model evaluation

The final model was evaluated using pcVPCs,25 which were
constructed by plotting the 10th, 50th and 90th percentiles (and their
corresponding 95% confidence intervals) of the predicted concentra-





9270  Wt
6
B ð1  1:11Þ iC7
FFM ðfemalesÞ ¼ 41:11 þ @h
Age1:1 A5  8780 þ ð244  BMIÞ
1 þ 7:1

ð2Þ
BMI ¼

2.5

tions from 1000 simulated datasets against time overlaid by the same
percentiles of the observed data. The precision of parameter
estimates was evaluated from the confidence intervals calculated
from nonparametric bootstrapping. To that end, 1000 bootstrap samples were simulated and used for the estimation of model parameters.

Wt

ð3Þ

ðHt=100Þ2

Runs with unsuccessful minimisation were excluded and substituted
with additional successful ones.

rﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Wt  Ht
BSA ¼
3600

ð4Þ

2.6

NFM ¼ FFM þ Ffat  ðWt  FFMÞ

|

Simulation of dosing regimens

ð5Þ
The final PK model was used to simulate the current guidelines of

where Ht is the height and Ffat is a model parameter that estimates

enoxaparin dosing in children, which is 1 mg/kg of Wt twice daily

the fractional contribution of fat mass to the NFM.

for children older than 2 months. The success rate of attaining the

Continuous covariates were normalised to the population median.

target, which is 4-hour post-dose aXa activity between 0.5 and

The influence of PMA on the maturation of clearance (CL) was

1 IU/mL after the first-dose and at steady-state dose, was calculated

evaluated using the sigmoid hyperbolic maturation function described

assuming no dose adjustment. The target activity was selected as

22

for maturation of glomerular filtration rate (Equation 6).

The

per the CHEST guidelines for antithrombotic therapy in neonates

covariates were added to the model using forward inclusion backward

and children.4 All simulations assumed infinite dose banding (doses

elimination:

were administered with infinite accuracy). Ten thousand virtual
patients were randomly sampled from the Third National Health and
PMAγi
Fage ¼
PMA50γ þ PMAγi

ð6Þ

Nutrition Examination Survey (NHANES III) database published by
the CDC.26 The sampled covariates were then used as a part of
the covariate model to generate group parameters. The fixed and

Here Fage is the fractional clearance adjustment for maturation for a

random effects of the final model, excluding RUV, were used to

child of a given post-menstrual age (PMAi ), γ is the sigmoidicity coeffi-

simulate the aXa time profiles in R v4.0.227 and deSolve package

cient that controls the steepness of the maturation curve (fixed at 3.4

v1.28.28 We note that RUV and parameter uncertainty (RSE) were

22

as per Anderson and Holford ) and PMA50 is the age at which

not included in the simulations since the aim of the simulations was

clearance is 50% mature (fixed at 47.7 weeks as per Anderson and

to compare the outcomes of different dosing regimens, which was

22

done using the same model. Therefore, inclusion of RUV and RSE in

Holford ).

the simulations was not expected to change the conclusion as to
which regimen was optimal.

2.4

|

Model selection

Dosing regimens based on age, FFM, BSA and a combination
of these were explored. The dose amount that had the highest

This analysis was performed in NONMEM v7.423 with PsN v5.0.024

rate of target achievement for each of these dose regimen types

and the first-order conditional estimation method with interaction

was estimated through iterative dose adjustments and success rate

was used. Residual unexplained variability (RUV) was modelled using

calculation. The highest target attainment rate for alternative

combined proportional and additive error models. The criteria for

dosing strategies was compared to current dosing guidelines for

model selection were (1) a reduction in the objective function value

both obese/overweight patients and normal-weight patients. The R

(OFV), (2) visual goodness-of-fit evaluation, (3) biological plausibility

code used in the simulation is provided in Supplement 1.

of parameter estimates and (4) precision of parameter estimates as
determined by the nonparametric bootstrapping-based confidence

3

intervals.

RE SU LT S

|

Comparison of the OFV for model selection was based on the
likelihood ratio test at the α ¼ 0:05 significance level. Since the

3.1

|

Evaluation of published models

difference in the OFV between two nested models is χ -distributed, a
2

difference of 3.84 units was considered equivalent to P = .05 for one

The re-estimated published models were able to capture the overall

degree of freedom.

data reasonably well, as shown by the pcVPC (Figure 2). However,
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F I G U R E 2 Prediction-corrected visual
predictive checks for the published models against
the whole study dataset. Dashed red lines
represent the 10th, 50th and 90th percentiles of
observed data. Solid black lines represent the
same percentiles of simulated data. Shaded areas
represent the 95% CI around the simulated
percentiles. Solid black dots represent the
observations

F I G U R E 3 Prediction-corrected visual predictive checks for the published models stratified by body size category (left, normal-weight
patients; right, overweight/obese patients). Dashed red lines represent the 10th, 50th and 90th percentiles of observed data. Solid black lines
represent the same percentiles of simulated data. Shaded areas represent the 95% CI around the simulated percentiles. Solid black dots represent
the observations

when pcVPCs were stratified by body size category, the models

significant improvement on model performance and resulted in

showed systematic underprediction of concentrations in overweight/

reduction in OFV of 522 and 366 points, respectively, compared to

obese patients which was not evident in the normal-weight group

the base model (see Appendix S2 for further details). Allowing CL and

(Figure 3).

V to co-vary by estimating a block covariance matrix reduced the
variance of both CL and V, lowered the additive residual error and
significantly reduced the OFV (P value = 0.0021). Bootstrap analysis

3.2

|

Population pharmacokinetic model

of the final model showed similar median values of the population
parameters to those estimated in the final model. All parameters were

The data were best described by a one-compartment model with

estimated with reasonable precision, as shown by the 95% CI, except

linear elimination and a combined additive and proportional error

for ωka , where the CI was relatively wide due to the limited amount of

model. Estimates of fixed and random effects parameters of the

data available in the absorption phase (Table 2). Additionally,

model are illustrated in Table 2. Allometric scaling of FFM on CL and

excluding data from patients with imputed height/weight did not

linear scaling of FFM on volume of distribution (V) yielded the most

significantly change the parameter estimates (Appendix S3). pcVPC
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plots for all patients (Figure 4) when stratified by patient size category

after the first dose and 72.6% at steady state. After the first dose,

(Figure 5) showed robust model performance. The NONMEM code

most out-of-range patients (93.8%) had subtherapeutic aXa activities.

file for the final model is included in Supplement 2.

Although obese patients had a higher success rate after the first
dose under SoC dosing than normal-weight patients (55.7% vs 43.4%),
a larger proportion had supratherapeutic aXa activities at steady state

3.3

|

Simulation of dosing regimens

(29.5% for overweight/obese vs 9% for normal-weight patients), as
illustrated in Table 3 and Figure 6.

Simulations from the final PK model showed that the current standard

These results suggest that the success rate could be optimised by

of care (SoC) dosing of 1 mg/kg twice daily achieved an overall

including a loading dose in the regimen to address subtherapeutic aXa

(in both body size groups) success rate of target attainment of 46.9%

activities after the first dose and decreasing the total dose administered to obese/overweight patients. Among the different dosing alternatives tested (see Appendix S4 for more details), the regimen that

TABLE 2
estimates

Final population pharmacokinetic model parameter

Parameter

ing dose followed by 1.2 mg/kg of FFM twice daily for maintenance
Estimate
(RSE)

Bootstrap mean
(95% CI)

(Figure 7). This regimen achieves similar aXa activities to the SoC regimen for normal-weight patients at steady state. However, the proposed regimen performs better after the first dose for both normal-

Fixed effects parameters
θCL (mL/h/20 kg FFM)

4.09 (4%)

4.09 (3.81-4.39)

θV (mL/20 kg FFM)

34.3 (7%)

34.19 (29-39.6)

θka (/h)

0.659 FIX

0.659 FIX

Allometric exponent
(θCL,FFM )

0.712 (4%)

0.71 (0.66-0.76)

22.9/15

22.64 (17.5-26.9)

Random effects parameters
ωCL (%)/shrinkage (%)

achieved the highest success rate was 1.8 mg/kg of FFM as the load-

weight and overweight/obese patients as well as at steady state for
overweight/obese patients (see Figure 8). The success rates for FFMbased dosing with the loading dose approach for both normal weight
and overweight/obese patients are summarised in Table 3.

4

|

DI SCU SSION

ωV (%)/shrinkage

33.4/15

33.4 (22.9-42.5)

This study developed a model to describe the pharmacokinetics of

ωka (%)/shrinkage

58.2/75

58.0 (26.9-92.6)

enoxaparin in overweight/obese children. The model described data

Corr (CL,V) (%)

100

100 (100-100)

well in both overweight/obese patients and normal-weight patients,

σ prop (%)/shrinkage

4.69/11

4.5 (1.5-7.5)

and had precisely estimated parameters. For the model, FFM was a

σ add (U/mL)/shrinkage

0.0059/11

0.0061
(0.0003-0.0124)

better descriptor than Wt for the effect of body size on the CL and V

Abbreviations: CI, confidence interval; FFM, fat-free mass; RSE, relative
standard error.

of enoxaparin in children.
Wt is often used to describe the influence of body size on clearance and as a scalar for drug doses. This practice requires the

F I G U R E 4 Prediction-corrected visual predictive checks for the final model against the whole dataset. Dashed red lines represent the 10th,
50th and 90th percentiles of observed data. Solid black lines represent the same percentiles of simulated data. Shaded areas represent the 95%
CI around the simulated percentiles. Solid black dots represent the observations. Note that observations outside the limits of the time axis are
omitted from the plot to enhance the visual interpretability. The limits of the time axis are determined based on the mid-points of the first and
last bin
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F I G U R E 5 Prediction-corrected visual
predictive checks for the final model stratified by
body size category (left, normal-weight patients;
right, overweight/obese patients). Dashed red
lines represent the 10th, 50th and 90th
percentiles of observed data. Solid black lines
represent the same percentiles of simulated data.
Shaded areas represent the 95% CI around the
simulated percentiles. Solid black dots represent
the observations

T A B L E 3 The success rate of attaining 4-hour post-dose aXa
activity within target under FFM dosing with a loading dose
(FFM-based) and SoC dosing
First dose

prevalence of obesity worldwide. In this study, CL was found to be
proportional to allometrically scaled FFM with an estimated exponent
of 0.71 (CI 0.66-0.76). It is reasonable to expect CL to scale linearly
with FFM as the elimination occurs primarily in the fat-free portion of

Steady state

the body. However, our analysis has shown that CL scales less than
Body size category

FFM-based

SoC

FFM-based

SoC

Normal body weight

71.5

43.4

77.5

75.5

(CI 0.66-0.76), which is not significantly different from the standard

Overweight/obese

72.5

55.7

76.7

65.2

value of 0.75.

Abbreviations: FFM, fat-free mass; SoC, standard of care.
Numbers are presented as percentages.

proportionally with FFM with an estimated exponent of 0.71

Due to the limited observations that were available in the absorption phase, it was not possible to precisely estimate the absorption
rate constant (ka), which was therefore fixed to 0.659/h.5 This has
probably contributed to the higher prediction percentiles compared

assumption that body composition is consistent across weight ranges

with observations in the first bin in overall (Figure 4) and stratified

and therefore clearance would vary proportionally with Wt. However,

pcVPCs (Figure 5). Nonetheless, observed percentiles still lie within

overweight/obese individuals have less metabolically active lean mass

the confidence intervals of the simulated percentiles. Additionally, a

per kilogram of Wt compared to normal-weight individuals and there-

high degree of correlation between CL and V (100%) was observed.

fore are likely to have less than proportional change in CL with

This is likely due to the high correlation of patient covariates (eg, age,

respect to Wt.6,7 Two population PK models of enoxaparin in children

weight, height and FFM) in this population.

have been published which use allometrically scaled Wt as a covariate

The primary mode of enoxaparin elimination is through glome-

However, when both models were fitted to our data-

rular filtration.29 This suggests that maturation of glomerular filtra-

set and evaluated using pcVPCs overlaid with the data, they per-

tion rate (GFR) would significantly impact enoxaparin clearance,

formed well overall but significantly underpredicted concentration in

especially in infants. However, in this analysis, serum creatinine

the overweight/obese group (see Figure 3). This is probably due to CL

data were not available and therefore an empirical GFR maturation

being overestimated as a result of the assumption of proportionality

function22 was used as a covariate on CL but did not achieve any

to Wt. Finding a more suitable body size descriptor in overweight/

significant improvement in model fitness. This is probably because

obese children is particularly important given the increasing

the FFM calculation includes age therefore summarises the effects

on clearance.

5,17
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F I G U R E 6 Simulations of aXa
activities from the final population PK
model for Wt-based dosing. The black line
represents the median predicted aXa
activity. Shaded areas represent the 80%,
60%, 40% and 20% prediction intervals.
Dashed red lines represent the
boundaries of the therapeutic target

F I G U R E 7 Simulations of aXa
activities from the final population PK
model for FFM-based dosing with loading
dose. The black line represents the
median predicted aXa activity. Shaded
areas represent the 80%, 60%, 40% and
20% prediction intervals. Dashed red lines
represent the boundaries of the
therapeutic target

of both size and maturation (Equations 1 and 2). In paediatric

Simulations from the final PK model showed two issues with the

patients with normal renal function (for size) further adjustment

current SoC dosing regimen. First, the low rate of target achievement

based on impaired renal function was not required.

after the first dose with a substantial proportion of patients attaining

FFM was also found to be the only significant covariate on

subtherapeutic aXa activities. Although the overall rate of target

V. This is consistent with its high hydrophilicity, which limits

attainment is similar to that of adults,32 plots of simulated data

30

distribution to blood, extracellular fluid and highly perfused tissues,

(Figure 6) show substantial room for improvement. Second, a signifi-

which are well represented by FFM.31

cantly higher proportion of overweight/obese individuals achieve
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F I G U R E 8 The distribution of aXa
activity 4 hours post-dose for the first
dose and at steady state for SoC dosing
and FFM-based dosing with a loading
dose. Dashed red lines represent the
boundaries of the therapeutic target. Wt,
total body weight; FFM, fat-free mass

supratherapeutic aXa activities at steady state compared to the

body size and drug dose are continuous variables, therefore

normal-weight group. Therefore, we recommend FFM-based dosing

discretising doses based on body size is likely to produce less than

with a loading dose. Simulations showed that this approach had a high

optimal outcomes.

target attainment success rate after the first dose and a significant

Based on the proportionality of CL with allometrically scaled

improvement in success rates in overweight/obese patient groups.

FFM, it is expected that patients on the lower end of the FFM range

The success rate under the proposed regimen is similar across body

(eg, neonates and infants) require a higher maintenance dose than the

size categories and the success rate in normal-weight patients under

recommended regimen. However, this has not been evaluated as it

the SoC regimen. This suggests that 70-74% is the highest success

was beyond the scope of this work.

rate achievable through covariate-based dosing given the variability in
enoxaparin pharmacokinetics.

Since enoxaparin is administered subcutaneously, it is expected
that obesity and/or maturation may influence on the rate and/or

Despite the identification of FFM as a covariate that better

extent of absorption. However, since there were limited observations

accounted for variability in enoxaparin pharmacokinetics, there is

in the absorption phase, it was not possible to determine such an

still significant unexplained BSV in PK parameters, including 22.9% of

effect. Although the value of the ka was fixed to the literature value,

variability in CL. Although relatively low compared to many PK

this value was obtained from studies that were not designed to study

analyses,33 such unexplained variability with a relatively narrow

the effect of obesity on enoxaparin absorption, and hence misspecifi-

target range resulted in 22.7-28.2% of patients outside the target

cation cannot be rolled out. Therefore, an appropriately designed trial

aXa activity under the proposed dosing regimen. Since no more

can confirm or dispute this and, more importantly, validate the

influential covariates were able to be identified in our analysis, it

proposed dosing regimen in overweight/obese children.

is only possible to increase the target attainment rates through a

Of note, the proposed dosing regimen aims to achieve a 4-hour

more strictly individualised approach such as adaptive feedback

post-dose aXa activity of 0.5-1 U/mL, assuming that this exposure is

control.34

associated with favourable clinical outcomes. However, such a target

Identification of FFM as a covariate on CL allowed the develop-

has not been validated in children and it is not known if overweight/

ment of dosing recommendations that could achieve the therapeutic

obese children would have different exposure-effect-outcome

target consistently in overweight/obese children, as with normal-

relationships to normal-weight children. A further clinical outcome

weight children. Such a unified dosing approach can be conveniently

study is warranted.

applied in clinical practice as it eliminates the need for the
additional categorisation of patients based on their body size before
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